Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

Rhea-AI Summary

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a biopharmaceutical company dedicated to rare diseases, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 1:00 PM EDT. David Cory, President and CEO, will lead the presentation. A live webcast will be available on Eiger's website, with a replay accessible one hour post-event. Eiger is focused on therapies for Hepatitis Delta Virus and has FDA approval for Zokinvy®, targeting Hutchinson-Gilford Progeria Syndrome.

PALO ALTO, Calif., July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and Chief Executive Officer of Eiger, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Wednesday, July 14, 2021 at 1:00 PM EDT.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab.  A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will also host virtual one-on-one meetings with investors.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3.

Zokinvy^® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Charles Butler
Vice President, Investor Relations and Corporate Communications
Email: cbutler@eigerbio.com
Phone: 1-650-272-6138

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-ladenburg-thalmann-2021-virtual-healthcare-conference-301326717.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When will Eiger BioPharmaceuticals present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference?

Eiger BioPharmaceuticals will present on July 14, 2021, at 1:00 PM EDT.

Who is presenting for Eiger BioPharmaceuticals at the conference?

David Cory, President and CEO of Eiger BioPharmaceuticals, will present.

How can I watch Eiger BioPharmaceuticals' presentation?

The presentation can be viewed live on Eiger's website under the 'Investors' tab.

What is Eiger BioPharmaceuticals focused on developing?

Eiger BioPharmaceuticals develops targeted therapies for serious rare and ultra-rare diseases.

What is Zokinvy® and its approval status?

Zokinvy® is Eiger's first FDA approved product for Hutchinson-Gilford Progeria Syndrome, with an MAA under review by the EMA.